Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

181. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W)

Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W) 18323500 2008 04 29 2008 05 29 2016 11 24 1524-4628 39 5 2008 May Stroke Stroke Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation (...) clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). 1482-6 10.1161/STROKEAHA.107.500199 In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation. However, because OAC carries important bleeding complications, risk stratification schemes have been devised to identify patients for whom the absolute benefits of OAC exceed its risks. Participants were risk-stratified

EvidenceUpdates2008

182. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.

Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. 18477783 2008 05 14 2008 05 20 2017 02 20 1538-3598 299 18 2008 May 14 JAMA JAMA Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. 2164-71 10.1001/jama.299.18.2164 The arteriovenous fistula is the preferred type of vascular access for hemodialysis because of lower thrombosis and infection rates and lower health care (...) expenditures compared with synthetic grafts or central venous catheters. Early failure of fistulas due to thrombosis or inadequate maturation is a barrier to increasing the prevalence of fistulas among patients treated with hemodialysis. Small, inconclusive trials have suggested that antiplatelet agents may reduce thrombosis of new fistulas. To determine whether clopidogrel reduces early failure of hemodialysis fistulas. Randomized, double-blind, placebo-controlled trial conducted at 9 US centers composed

JAMA2008

183. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. 18753638 2008 09 18 2008 09 24 2016 12 15 1533-4406 359 12 2008 Sep 18 The New England journal of medicine N. Engl. J. Med. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. 1238-51 10.1056/NEJMoa0805002 Recurrent stroke is a frequent, disabling event after ischemic stroke. This study compared the efficacy and safety of two antiplatelet regimens--aspirin plus extended-release (...) dipyridamole (ASA-ERDP) versus clopidogrel. In this double-blind, 2-by-2 factorial trial, we randomly assigned patients to receive 25 mg of aspirin plus 200 mg of extended-release dipyridamole twice daily or to receive 75 mg of clopidogrel daily. The primary outcome was first recurrence of stroke. The secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes. Sequential statistical testing of noninferiority (margin of 1.075), followed by superiority testing

NEJM2008 Full Text: Link to full Text with Trip Pro

184. Does clopidogrel rather than aspirin plus a proton-pump inhibitor reduce the frequency of gastrointestinal complications after cardiac surgery?

Does clopidogrel rather than aspirin plus a proton-pump inhibitor reduce the frequency of gastrointestinal complications after cardiac surgery? BestBets: Does clopidogrel rather than aspirin plus a proton-pump inhibitor reduce the frequency of gastrointestinal complications after cardiac surgery? Does clopidogrel rather than aspirin plus a proton-pump inhibitor reduce the frequency of gastrointestinal complications after cardiac surgery? Report By: Maren Ziegelin, Andreas Hoschtitzky, Joel (...) Dunning, and Tim Hooper - Specialist Registrars in Cardiothoracic Surgery Search checked by Joel Dunning - Specialist Registrar in Cardiothoracic Surgery RCS Institution: Department of Cardiothoracic Surgery, Wythenshawe Hospital, Manchester and ames Cook University Hospital, Middlesbrough Date Submitted: 24th July 2007 Date Completed: 17th October 2007 Last Modified: 17th October 2007 Status: Green (complete) Three Part Question In patients undergoing [cardiac surgery] is [clopidogrel superior

BestBETS2007

185. Does Clopidogrel Increase Morbidity and Mortality After Minor Head Injury

Does Clopidogrel Increase Morbidity and Mortality After Minor Head Injury BestBets: Does Clopidogrel Increase Morbidity and Mortality After Minor Head Injury Does Clopidogrel Increase Morbidity and Mortality After Minor Head Injury Report By: Dr Richard Parris - Consultant in Emergency Medicine Search checked by Dr Zia Hassan - Registrar in Emergency Medicine, Hope Hospital Institution: Royal Bolton Hospital Date Submitted: 17th February 2006 Date Completed: 29th May 2007 Last Modified: 12th (...) April 2007 Status: Green (complete) Three Part Question In a patient with a [head injury], does concurrent [treatment with clopidogrel] [increase morbidity and mortality]? Clinical Scenario A 78-year old male presents to the Emergency Department in a coma two days after a minor head injury. You note he is taking clopidogrel for treatment of his ischaemic heart disease. CT scan shows a large sub-dural haematoma. You wonder whether the clopidogrel has contributed to the development of this haematoma

BestBETS2007

186. Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction

Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction Article Text Therapeutics Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute

Evidence-Based Medicine (Requires free registration)2007

187. Role of clopidogrel in managing atherothrombotic cardiovascular disease.

Role of clopidogrel in managing atherothrombotic cardiovascular disease. Aspirin is the most widely used antiplatelet agent for preventing and treating vascular events. The thienopyridine derivatives, ticlopidine and clopidogrel, are a suitable alternative in patients who are intolerant to aspirin, and clopidogrel exhibits better tolerability than ticlopidine. The available evidence from randomized trials indicates that dual therapy with clopidogrel and aspirin is modestly but significantly (...) of platelet glycoprotein IIb/IIIa inhibitors, and the exact mechanism and clinical relevance of clopidogrel resistance are unclear.

Annals of Internal Medicine2007

188. Should high risk patients receive clopidogrel as well as aspirin post coronary arterial bypass grafting?

Should high risk patients receive clopidogrel as well as aspirin post coronary arterial bypass grafting? BestBets: Should high risk patients receive clopidogrel as well as aspirin post coronary arterial bypass grafting? Should high risk patients receive clopidogrel as well as aspirin post coronary arterial bypass grafting? Report By: Babu Kunadian, Andrew R. Thornley, Thotala N. Babu - Specialist Registrars in Cardiothoracic Surgery Search checked by Joel Dunning - Cardiothoracic Registrar RCS (...) Institution: Department of Cardiothoracic Surgery, James Cook University Hospital and Department of Cardiology, Lincoln Medical Health Center, New York Date Submitted: 21st December 2006 Date Completed: 13th February 2007 Last Modified: 13th March 2007 Status: Green (complete) Three Part Question In patients post [urgent coronary arterial bypass grafting] should [clopidogrel be given in addition to aspirin] to reduce the chance of [thrombotic complications]. Clinical Scenario You are reviewing a 55-year

BestBETS2007

189. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.

Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. CONTEXT: Recent studies of drug-eluting intracoronary stents suggest that current antiplatelet regimens may not be sufficient to prevent late stent thrombosis. OBJECTIVE: To assess the association between clopidogrel use and long-term clinical outcomes of patients receiving drug-eluting stents (DES) and bare-metal stents (BMS) for treatment of coronary artery disease. DESIGN, SETTING, AND PATIENTS (...) revascularization) at 6- and 12-month follow-up. At these points, patients were divided into 4 groups based on stent type and self-reported clopidogrel use: DES with clopidogrel, DES without clopidogrel, BMS with clopidogrel, and BMS without clopidogrel. MAIN OUTCOME MEASURES: Death, nonfatal MI, and the composite of death or MI at 24-month follow-up. RESULTS: Among patients with DES who were event-free at 6 months (637 with and 579 without clopidogrel), clopidogrel use was a significant predictor of lower

JAMA2007

190. Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials

Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials Helton T J, Bavry A A, Kumbhani D J, Duggal S, Roukoz H, Bhatt D L CRD summary The authors (...) concluded that the addition of clopidogrel to aspirin slightly reduces all-cause and cardiovascular mortality in patients with ST-elevation myocardial infarction (STEMI), and modestly reduces myocardial infarction and stroke in patients with cardiovascular disease, but also increases bleeding. The review was generally well-conducted, but the lack of results data undermines the conclusion about the subgroup of STEMI patients. The other conclusions appear reliable. Authors' objectives To compare

DARE.2007

191. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention

Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention Lotrionte M, Biondi-Zoccai G G, Agostoni P, Abbate A, Angiolillo D J, Valgimigli M, Moretti C, Meliga E, Cuisset T, Alessi M C, Montalescot G, Collet J P, Di Sciascio G (...) , Waksman R, Testa L, Sangiorgi G, Laudito A, Trevi G P, Sheiban I CRD summary The authors concluded that a higher clopidogrel loading dose regimen is superior to a standard (300 mg) loading regimen in patients undergoing percutaneous coronary intervention, and that the benefits are greater in patients at higher risk. This was a well-conducted review and the conclusions are likely to be reliable. Authors' objectives To compare high and standard clopidogrel loading regimens in patients undergoing

DARE.2007

192. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis

Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis Snoep J D, Hovens M M, Eikenboom J C, van der Bom J G, Jukema J W, Huisman M (...) V CRD summary The authors concluded that about one in five patients who undergo percutaneous coronary intervention with stenting are labelled ex vivo clopidogrel unresponsive and are at increased risk of poorer cardiovascular outcomes. Differences between the studies, lack of systematic reporting of study quality, and pooling of different study designs make it difficult to determine the reliability of these conclusions. Authors' objectives To determine the prevalence of clopidogrel

DARE.2007

193. Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression

Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression Biondi-Zoccai G G, Lotrionte M, Agostoni P, Valgimigli M, Abbate A, Sangiorgi G, Moretti C (...) , Sheiban I CRD summary This review concluded that clopidogrel given with an initial loading dose is associated with a reduced risk of death or heart attack compared with ticlopidine in patients undergoing coronary stenting. The review had methodological limitations and relied mainly on short-term studies with small numbers of events, hence the conclusions should be treated with caution. Authors' objectives To assess the effectiveness of clopidogrel versus ticlopidine in patients undergoing coronary

DARE.2007

194. Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany

Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany Bruggenjurgen B, Lindgren P, Ehlken B, Rupprecht H J, Willich S N Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined 1-year of clopidogrel added to acetylsalicylic acid (ASA) in patients with acute coronary syndrome without ST-segment elevation. Clopidogrel plus ASA was compared with ASA monotherapy. Type of intervention Secondary prevention

NHS Economic Evaluation Database.2007

195. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials

Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials Berg H, Lindgren P, Spiesser J, Parry D, Jonsson B Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study evaluated two treatment options for patients with ST-segment elevation myocardial infarction (STEMI). The options were clopidogrel in combination with acetylsalicylic acid (ASA) and ASA alone. Type

NHS Economic Evaluation Database.2007

196. Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention

Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention Heeg B M, Peters R J, Botteman M, van Hout B A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared the use of short-term versus long-term therapy with clopidogrel, in patients undergoing percutaneous coronary intervention, either electively or as patients with acute coronary syndrome. The authors concluded that long-term clopidogrel resulted in cost savings and increased the number of life-years and QALYs gained compared with short-term clopidogrel treatment

NHS Economic Evaluation Database.2007

197. Clopidogrel after drug-eluting stent implantation

Clopidogrel after drug-eluting stent implantation Clopidogrel after drug-eluting stent implantation | Therapeutics Initiative Independent Healthcare Evidence > > Clopidogrel after drug-eluting stent implantation Background information of the condition: Drug Eluting Stents (DES) Implantation DES were invented to reduce restenosis compared to bare metal stents (8% vs. 25% , respectively). The process responsible for stent stenosis is delayed with drugs (sirolimus [rapamycin] and paclitaxel (...) ); however this benefit is offset by harm due to stent thrombosis (0.2-1.1%). Dual antiplatelet therapy is recommended to decrease the rate of stent thrombosis. Drug (Product Monograph ) Category Clopidogrel is categorized as platelet aggregation inhibitor. Mechanism of action : Clopidogrel selectively inhibits the binding of ADP to its platelet receptor and the subsequent ADP-mediated activation of the glycoprotein IIb-IIIa complex, thereby inhibiting platelet aggregation. Indication : Clopidogrel

Therapeutics Letter2007

198. Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial

Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial Kolm P, Yuan Y, Veledar E, Mehta S R, O'Brien J A, Weintraub W S Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to determine the long-term cost-effectiveness of clopidogrel plus acetylsalicylic acid (ASA) compared with ASA alone. The authors concluded that clopidogrel plus ASA therapy was cost-effective compared with ASA alone. Overall the methodology was good

NHS Economic Evaluation Database.2007

199. Should clopidogrel be stopped prior to urgent cardiac surgery?

Should clopidogrel be stopped prior to urgent cardiac surgery? BestBets: Should clopidogrel be stopped prior to urgent cardiac surgery? Should clopidogrel be stopped prior to urgent cardiac surgery? Report By: Babu Kunadian, Andrew R. Thornley, Marios Tanos - Cardiothoracic Registrars Search checked by Joel Dunning - Cardiothoracic Registrar RCS Institution: Department of Cardiothoracic Surgery, James Cook University Hospital and Freeman Hospital, Newcastle-upon-Tyne Date Submitted: 18th (...) September 2006 Date Completed: 26th October 2006 Last Modified: 18th September 2006 Status: Green (complete) Three Part Question In patients undergoing [urgent Coronary Arterial Bypass grafting] can surgery [with recent clopidogrel administration] be safely performed [early without excessive bleeding] Clinical Scenario You have been asked to perform urgent CABG on a 72 year old gentleman who has just undergone angiography for acute coronary syndrome. He had been admitted that day with chest pain at rest

BestBETS2007